{"schema_version":"secwatch.filing_event.v1","accession":"0001510964-23-000012","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.324530+00:00","generated_at":"2026-06-17T10:19:16.079823+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CV Sciences FY2022 revenue $16.2M, down 19% YoY; operating loss narrows to $6.8M","bullets":["Revenue $16.2M for FY2022 vs $20.0M in 2021 (-19%); Q4 revenue $3.9M, up 3% sequentially.","Gross margin 34.2% in FY2022 vs 43.0% in 2021; Q4 gross margin 40.4%.","Operating expenses cut 54% to $12.4M; operating loss improved to $6.8M from $18.4M.","Cash balance $0.6M at year-end; Q4 generated $0.2M positive operating cash flow.","Regained #1 hemp extract brand in natural retail; launched new products; evaluating M&A."],"urls":{"canonical":"https://secwatch.observer/filing/0001510964-23-000012","json":"https://secwatch.observer/filing/0001510964-23-000012.json","markdown":"https://secwatch.observer/filing/0001510964-23-000012.md","text":"https://secwatch.observer/filing/0001510964-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000012/0001510964-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000012/cvsi-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:19:16.079823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8b528a7a7e4309c59682cf79714200e059b856c","claim":"CV Sciences, Inc. reported the year and quarter ended December 31, 2022 results: revenue $16.2 million.","evidence_excerpt":"its financial results for the year and quarter ended December 31, 2022. Fiscal 2022, Fourth Quarter 2022 and Recent Financial and Operating Highlights • Generated revenue of $16.2 million for fiscal year 2022 compared to $20.0 million for 2021; Revenue of $3.9 million for the fourth quarter 2022 sequential increase of 3% from $3.8 million in the third quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000151096423000012/0001510964-23-000012-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year and quarter ended December 31, 2022"},{"label":"Revenue","value":"$16.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}